Decision Theoretic Designs for Phase II Clinical Trials with Multiple Outcomes
Authors:
- 1 September 1999
- journal article
- Published by Oxford University Press (OUP) in Biometrics
- Vol. 55 (3) , 971-977
Abstract
Summary. In many phase II clinical trials, it is essential to assess both efficacy and safety. Although several phase II designs that accommodate multiple outcomes have been proposed recently, none are derived using decision theory. This paper describes a Bayesian decision theoretic strategy for constructing phase II designs based on both efficacy and adverse events. The gain function includes utilities assigned to patient outcomes, a reward for declaring the new treatment promising, and costs associated with the conduct of the phase II trial and future phase III testing. A method for eliciting gain function parameters from medical collaborators and for evaluating the design's frequentist operating characteristics is described. The strategy is illustrated by application to a clinical trial of peripheral blood stem cell transplantation for multiple myeloma.Keywords
This publication has 25 references indexed in Scilit:
- A Bayesian group sequential design for a multiple arm randomized clinical trialStatistics in Medicine, 1995
- Bayesian sequential monitoring designs for single‐arm clinical trials with multiple outcomesStatistics in Medicine, 1995
- Sample sizes for phase ii clinical trials derived from Bayesian decision theoryStatistics in Medicine, 1994
- Group Sequential Clinical Trials: A Classical Evaluation of Bayesian Decision-Theoretic DesignsJournal of the American Statistical Association, 1994
- Decision making during a Phase III randomized controlled trialControlled Clinical Trials, 1994
- An optimal three‐stage design for phase II clinical trialsStatistics in Medicine, 1994
- Application of the triangular test to phase II cancer clinical trialsStatistics in Medicine, 1990
- Corrected Loss Calculation for Phase II Trials1990
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989
- Why Isn't Everyone a Bayesian?The American Statistician, 1986